

Stefanie R Bailey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2957749/publications.pdf>

Version: 2024-02-01

28
papers

2,002
citations

471509

17
h-index

752698

20
g-index

28
all docs

28
docs citations

28
times ranked

3418
citing authors

#	ARTICLE	IF	CITATIONS
1	Blockade or Deletion of IFN γ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2022, 3, 136-153.	5.0	46
2	CAR T cell killing requires the IFN γ R pathway in solid but not liquid tumours. <i>Nature</i> , 2022, 604, 563-570.	27.8	150
3	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. <i>Cancer Cell</i> , 2022, 40, 494-508.e5.	16.8	54
4	Abstract 569: Mesothelin CAR T cells secreting FAP specific T cell engaging molecule (TEAM) target pancreatic cancer and its tumor microenvironment (TME). <i>Cancer Research</i> , 2022, 82, 569-569.	0.9	0
5	CRISPR screen identifies loss of IFN γ R signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors. , 2021, 9, A234-A234.		0
6	Blocking IFN γ in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity without Compromising Therapeutic Efficacy in CD19 +malignancies. <i>Blood</i> , 2021, 138, 1723-1723.	1.4	2
7	Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia. <i>Blood</i> , 2021, 138, 405-405.	1.4	1
8	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. , 2020, 8, e000990.		13
9	Identification of human CD4 ⁺ T cell populations with distinct antitumor activity. <i>Science Advances</i> , 2020, 6, .	10.3	27
10	CD26 enzymatic activity modulates efficient migration of adoptively transferred T cells to solid tumors. , 2020, 8, A549-A549.		1
11	Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies. , 2020, 8, A815-A815.		1
12	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. <i>Nature Biotechnology</i> , 2019, 37, 1049-1058.	17.5	347
13	Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. <i>Oncology Reviews</i> , 2019, 13, 430.	1.8	9
14	Gene editing for immune cell therapies. <i>Nature Biotechnology</i> , 2019, 37, 1425-1434.	17.5	147
15	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. , 2019, 7, 304.		181
16	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. <i>Clinical Cancer Research</i> , 2019, 25, 7046-7057.	7.0	56
17	When worlds collide: Th17 and Treg cells in cancer and autoimmunity. <i>Cellular and Molecular Immunology</i> , 2018, 15, 458-469.	10.5	331
18	Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. <i>Transplantation</i> , 2017, 101, e75-e85.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Human CD26 ^{high} T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. <i>Nature Communications</i> , 2017, 8, 1961.	12.8	67
20	PI3K $\hat{\imath}$ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8 ⁺ T Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1221.	4.8	56
21	$\hat{\imath}$ ² -catenin and PI3K $\hat{\imath}$ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. <i>JCI Insight</i> , 2017, 2, .	5.0	35
22	Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. <i>JCI Insight</i> , 2017, 2, e90772.	5.0	54
23	The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies. <i>Journal of Immunology Research and Therapy</i> , 2017, 2, 68-79.	1.0	20
24	Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8 ⁺ T cells without host preconditioning. , 2016, 4, 6.		23
25	Exploiting IL-17-producing CD4 ⁺ and CD8 ⁺ T cells to improve cancer immunotherapy in the clinic. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 247-259.	4.2	35
26	Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. <i>Clinical Cancer Research</i> , 2015, 21, 2546-2557.	7.0	25
27	Th17 Cells in Cancer: The Ultimate Identity Crisis. <i>Frontiers in Immunology</i> , 2014, 5, 276.	4.8	257
28	Reducing CD73 Expression by IL1 $\hat{\imath}$ ² -Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors. <i>Cancer Research</i> , 2014, 74, 6048-6059.	0.9	49